Breaking News, Collaborations & Alliances

Teva, Fosun Pharma Partner to Develop Immuno-Oncology Therapy

The Fosun Pharma-Teva collaboration agreement aims to accelerate clinical data generation for TEV-56278 and develop Anti-PD1-IL2 Therapy.

By: Rachel Klemovitch

Assistant Editor

Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that the companies, through their respective subsidiaries, have entered a strategic partnership. Together, the companies will develop an investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy, as well as accelerate clinical data generation. Teva’s internally developed ATTENUKINE technology provides a new mechanism of action, potentially offering high efficacy and low toxicity in a broad arra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters